DAFTAR PUSTAKA

Abdel-Misih, S.R.Z., Bloomston, M., 2010. Liver anatomy. Surg. Clin. North Am. 90, 643–653. https://doi.org/10.1016/j.suc.2010.04.017

Allen, A.M., Van Houten, H.K., Sangaralingham, L.R., Talwalkar, J.A., McCoy, R.G., 2018. Healthcare Cost and Utilization in Nonalcoholic Fatty Liver Disease: Real-World Data From a Large U.S. Claims Database. Hepatology 68, 2230–2238. https://doi.org/10.1002/hep.30094

Alves-Bezerra, M., Cohen, D.E., 2017. Triglyceride Metabolism in the Liver. Compr. Physiol. 8, 1–8. https://doi.org/10.1002/cphy.c170012

Aggarwal, A., & Bagri, N. (2022). In response to the article “The relationship between renal sinus lipomatosis detected at abdominal computed tomography and abdominal visceral and subcutaneous fat accumulation and metabolic risk factors”. Pol J Radiol 2020; 85: e62-e66. *Polish Journal of Radiology*, *87*(1), e232. https://doi.org/10.5114/pjr.2022.115807

Alberto, C. C. L., Iaarah, M. G., Eugenia, I. C. M., Julio, T. R., Víctor, A. A., Mario, R. C., & Julio, L. R. (2021). Clinical relevance of lipid panel and aminotransferases in the context of hepatic steatosis and fibrosis as measured by transient elastography (fibroscan®). *Journal of Medical Biochemistry*, *40*(1), 40–66. https://doi.org/10.5937/jomb0-24689

Alvarez, G. A. S., Galvez, S. M. P., Mora, U. G., Contreras, A. D. C., Rosas, C. D., Priego-Parra, B. A., Romero, A. T., Balmori, M. A., Dietlen, F. R., Vazquez, S. E. M., Guerrero, I. O. M., Chi-Cervera, L. A., Reyes, R. B., Roriguez, L. A. M., Chavez, M. E. I., & Troche, J. M. R. (2022). Higher cardiovascular risk scores and liver fibrosis risk estimated by biomarkers in patients with metabolic-dysfunction-associated fatty liver disease. *World Journal of Hepatology*, *14*(8), 1633–1642. https://doi.org/10.4254/wjh.v14.i8.1633

Antunes, C., Azadfard, M., Hoilat, G.J., Gupta, M., 2022. Fatty Liver. Treasure Island (FL).

Arshad, T., Golabi, P., Henry, L., Younossi, Z.M., 2020. Epidemiology of Non-
holic Fatty Liver Disease in North America. Curr. Pharm. Des. 2633, 993–
https://doi.org/10.2174/1381612826666200303114934

, Ahmed, Z., Arora, S., Haas, A., Kuo, Y.-F., Kamath, P.S., Singal, A.K.,
. NASH Is the Most Rapidly Growing Etiology for Acute-on-Chronic Liver

Failure-Related Hospitalization and Disease Burden in the United States: A Population-Based Study. Liver Transplant. Off. Publ. Am. Assoc. Study Liver Dis. Int. Liver Transplant. Soc. 25, 695–705. https://doi.org/10.1002/lt.25443

Bataller, R., & Brenner, D. A. (2005). Liver fibrosis. *The Journal of Clinical Investigation*, *115*(2), 209–218. https://doi.org/10.1172/JCI24282

Boëlle, P. Y., Debray, D., Guillot, L., Clement, A., & Corvol, H. (2019). Cystic Fibrosis Liver Disease: Outcomes and Risk Factors in a Large Cohort of French Patients. *Hepatology*, *69*(4), 1648–1656. https://doi.org/10.1002/hep.30148

Baek, J., Jung, S.J., Shim, J.-S., Jeon, Y.W., Seo, E., Kim, H.C., 2020. Comparison of Computed Tomography-based Abdominal Adiposity Indexes as Predictors of Non-alcoholic Fatty Liver Disease Among Middle-aged Korean Men and Women. J. Prev. Med. Public Health 53, 256–265. https://doi.org/10.3961/jpmph.20.140

Belew, G.D., Jones, J.G., 2022. De novo lipogenesis in non-alcoholic fatty liver disease: Quantification with stable isotope tracers. Eur. J. Clin. Invest. 52, e13733. https://doi.org/10.1111/eci.13733

Benedict, M., Zhang, X., 2017. Non-alcoholic fatty liver disease: An expanded review. World J. Hepatol. 9, 715–732. https://doi.org/10.4254/wjh.v9.i16.715

Braude, M., Roberts, S., Majeed, A., Lubel, J., Prompen, J., Dev, A., Sievert, W., Bloom, S., Gow, P., Kemp, W., 2023. Liver stiffness (Fibroscan®) is a predictor of all-cause mortality in people with non-alcoholic fatty liver disease. Liver Int. 43, 90–99. https://doi.org/10.1111/liv.15415

Carr, R.M., Oranu, A., Khungar, V., 2016. Nonalcoholic Fatty Liver Disease: Pathophysiology and Management. Gastroenterol. Clin. North Am. 45, 639–652. https://doi.org/10.1016/j.gtc.2016.07.003

Castéra, L., Foucher, J., Bernard, P., Carvalho, F., Allaix, D., Merrouche, W., Couzigou, P., de Lédinghen, V., 2010. Pitfalls of liver stiffness measurement: a 5-year prospective study of 13,369 examinations. Hepatology 51, 828–835.

Caprio, S. (1999). Relationship between abdominal visceral fat and metabolic risk ors in obese adolescents. *American Journal of Human Biology*, *11*(2), -266. https://doi.org/10.1002/(sici)1520-6300(1999)11:2<259::aid-13>3.3.co;2-n

e, P., Devanand, V., Chelladurai, A., Balasubramaniam, S., S, S.,

Nazarene, A., & Vivekkumar, P. (2022). Abdominal fat distribution and its relationship to sagittal abdominal diameter (SAD) and SAD-height ratio – An analytical cross-sectional study in the South Indian population. *National Journal of Physiology, Pharmacy and Pharmacology*, *0*, 1. https://doi.org/10.5455/njppp.2022.12.062951202217862022

Chen, D. Z., Ganapathy, A., Nayak, Y., Mejias, C., Bishop, G. L., Mellnick, V. M., & Ballard, D. H. (2023). Analysis of Superficial Subcutaneous Fat Camper's and Scarpa's Fascia in a United States Cohort. *Journal of Cardiovascular Development and Disease*, *10*(8). https://doi.org/10.3390/jcdd10080347

Chiyanika, C., Chan, D. F. Y., Hui, S. C. N., So, H. kwan, Deng, M., Yeung, D. K. W., Nelson, E. A. S., & Chu, W. C. W. (2020). The relationship between pancreas steatosis and the risk of metabolic syndrome and insulin resistance in Chinese adolescents with concurrent obesity and non-alcoholic fatty liver disease. *Pediatric Obesity*, *15*(9). https://doi.org/10.1111/ijpo.12653

Chou, Y. T., Sun, Z. J., Shen, W. C., Yang, Y. C., Lu, F. H., Chang, C. J., Li, C. Y., & Wu, J. S. (2022). Cumulative Betel Quid Chewing and the Risk of Significant Liver Fibrosis in Subjects With and Without Metabolic Syndrome. *Frontiers in Nutrition*, *9*. https://doi.org/10.3389/fnut.2022.765206

Ciardullo, S., Oltolini, A., Cannistraci, R., Muraca, E., & Perseghin, G. (2022). Sex-related association of nonalcoholic fatty liver disease and liver fibrosis with body fat distribution in the general US population. *American Journal of Clinical Nutrition*, *115*(6), 1528–1534. https://doi.org/10.1093/ajcn/nqac059

Cristóbal Serrano, G., Francisco Barrera, M., Riquelme, C., Hugo Vidal, A., Labbé, P., Francisco Cruz, O., Marco Arrese, J., Pablo Irarrázaval, M., Cristián Tejos, N., & Sergio Uribe, A. (2012). Volumetric measurement of abdominal visceral fat by MRI and its relation to transient elastography in a diabetic population. *Revista Chilena de Radiologia*, *17*(4), 183–191. https://doi.org/10.4067/s0717-93082011000400008

Castéra, L., Vergniol, J., Foucher, J., Le Bail, B., Chanteloup, E., Haaser, M., Darriet, M., Couzigou, P., De Lédinghen, V., 2005. Prospective comparison ansient elastography, Fibrotest, APRI, and liver biopsy for the assessment fibrosis in chronic hepatitis C. Gastroenterology 128, 343–350. s://doi.org/10.1053/j.gastro.2004.11.018

..W., 2021. Advances in Understanding of the Role of Lipid Metabolism in

Aging. Cells 10. https://doi.org/10.3390/cells10040880

Das NK, Islam AFMN, & Zaki KMJ. (2023). Relationship between Liver Stiffness Measured by Fibroscan and the Presence and Grading of Esophageal Varices by Endoscopy in Patients with Liver Cirrhosis. *The Journal of Sylhet Women's Medical College*, *13*(Number 2), 84–89. https://doi.org/10.47648/jswmc2023v13-02-81

Davis, L. (2017). *The relationship between BMI/body composition and survival of heart failure patients*.

Dehnavi, Z., Barghchi, H., Roudi, F., Naseri, M. B., Ostad, A. N., Khorasanchi, Z., Nematy, M., & Razmpour, F. (2021). On the relationship between non-alcoholic fatty liver disease with body composition and bone mineral density in overweight/obese adolescents. *Hepatitis Monthly*, *21*(3). https://doi.org/10.5812/hepatmon.112184

Dai, W., Ye, L., Liu, A., Wen, S.W., Deng, J., Wu, X., Lai, Z., 2017. Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: A meta-analysis. Medicine (Baltimore). 96, e8179. https://doi.org/10.1097/MD.0000000000008179

DeBose-Boyd, R.A., Ye, J., 2018. SREBPs in Lipid Metabolism, Insulin Signaling, and Beyond. Trends Biochem. Sci. 43, 358–368. https://doi.org/10.1016/j.tibs.2018.01.005

Degos, F., Perez, P., Roche, B., Mahmoudi, A., Asselineau, J., Voitot, H., Bedossa, P., 2010. Diagnostic accuracy of FibroScan and comparison to liver fibrosis biomarkers in chronic viral hepatitis: A multicenter prospective study (the FIBROSTIC study). J. Hepatol. 53, 1013–1021. https://doi.org/10.1016/j.jhep.2010.05.035

Dietrich, C.F., 2022. Noninvasive assessment of hepatic fibrosis: Ultrasound-based elastography - UpToDate [WWW Document]. UpToDate. URL https://www.uptodate.com/contents/noninvasive-assessment-of-hepatic-fibrosis-ultrasound-based-elastography?search=fibroscan&source=search_result&selectedTitle=2~47

age_type=default&display_rank=2#H8550276 (accessed 5.1.23).

C.F., Bamber, J., Berzigotti, A., Bota, S., Cantisani, V., Castera, L., grove, D., Ferraioli, G., Friedrich-Rust, M., Gilja, O.H., Goertz, R.S., as, T., De Knegt, R., De Ledinghen, V., Piscaglia, F., Procopet, B.,

Saftoiu, A., Sidhu, P.S., Sporea, I., Thiele, M., 2017. EFSUMB Guidelines and Recommendations on the Clinical Use of Liver Ultrasound Elastography, Update 2017 (Long Version), Ultraschall in der Medizin. https://doi.org/10.1055/s-0043-103952

Doval, E., Lopez, S.R., Albarran, A., Sosa, E., Ramirez, C., Ferreira, A., Espinosa, E., 2021. Changes in Visceral Fat and Its Correlation With Changes in Metabolic Variables After Bariatric Surgery. J. Endocr. Soc. https://doi.org/10.1210/jendso/bvab048.012

Emamat, H., Farhadnejad, H., Movahedian, M., Tangestani, H., Mirmiran, P., & Hekmatdoost, A. (2020). Dietary sodium intake in relation to non-alcoholic fatty liver disease risk: a case-control study. *Nutrition and Food Science*, *51*(3), 541–550. https://doi.org/10.1108/NFS-05-2020-0183

ENZYME, A. S. O. S. O. A. O. M. R. F. A. D. O. H. S. W. R. O. L. E. A. O. M. R. F. A. D. O. H. S. W. R. O. L. (2023). *A STUDY ON ASSOCIATION OF METABOLIC RISK FACTORS AND DEGREE OF HEPATIC STEATOSIS WITH RISE OF LIVER ENZYME*.

Fabbrini, E., Sullivan, S., Klein, S., 2010. Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology 51, 679–689. https://doi.org/10.1002/hep.23280

Feingold, K.R., 2022. Lipid and Lipoprotein Metabolism. Endocrinol. Metab. Clin. North Am. 51, 437–458. https://doi.org/10.1016/j.ecl.2022.02.008

Fitzpatrick, E., Dhawan, A., 2014. Noninvasive biomarkers in non-alcoholic fatty liver disease: current status and a glimpse of the future. World J. Gastroenterol. 20, 10851–10863. https://doi.org/10.3748/wjg.v20.i31.10851

Fernandes, S. A., Tovo, C. V., da Silva, A. L. M., Pinto, L. P., Carteri, R. B., & Mattos, A. A. (2022). Relationship between phase angle, steatosis, and liver fibrosis in patients coinfected with human immunodeficiency virus/hepatitis C virus. *World Journal of Hepatology*, *14*(6), 1173–1181. https://doi.org/10.4254/wjh.v14.i6.1173

Fernando, J. N., Alba, R. L., & Alba, W. (2019). Factors associated with the severity ndings on hepatic transient elastography among persons with type 2 etes and fatty liver. *Journal of the ASEAN Federation of Endocrine eties*, *34*(2), 134–143. https://doi.org/10.15605/jafes.034.02.03

3., Kleiner, D.E., 2020. Liver Histology: Diagnostic and Prognostic

Features. Clin. Liver Dis. 24, 61–74. https://doi.org/10.1016/j.cld.2019.09.004

Graffy, P.M., Pickhardt, P.J., 2016. Quantification of hepatic and visceral fat by CT and MR imaging: relevance to the obesity epidemic, metabolic syndrome and NAFLD. Br. J. Radiol. 89, 20151024. https://doi.org/10.1259/bjr.20151024

Gadhavi, R., Solanki, D., Rami, K., Bhagora, S., & Thakor, N. (2015). Relationship between blood pressure and BMI: a cross sectional study among government employees of Gujarat state, India. *International Journal of Research in Medical Sciences*, 1637–1640. https://doi.org/10.18203/2320-6012.ijrms20150243

Gürbüz, A. F., Keven, A., Elasan, S., & Çevikol, C. (2023). Evaluation of the relationship between abdominal fat distribution and osteoporotic vertebral compression fracture with MRI. *Skeletal Radiology*, *52*(6), 1203–1210. https://doi.org/10.1007/s00256-022-04247-7

Hu, Q., Han, K., Shen, J., Sun, W., Gao, L., & Gao, Y. (2023). Association of weight-adjusted-waist index with non-alcoholic fatty liver disease and liver fibrosis: a cross-sectional study based on NHANES. *European Journal of Medical Research*, *28*(1). https://doi.org/10.1186/s40001-023-01205-4

HUANG, Z., LEE, C. H., FONG, H. Y., & LAM, K. S. (2018). Association between Metabolic Syndrome Components and Indices of Liver Steatosis and Stiffness by Transient Elastography in Patients with Type 2 Diabetes and Imaging-Confirmed Nonalcoholic Fatty Liver Disease. *Diabetes*, *67*(Supplement_1). https://doi.org/10.2337/db18-617-p

Hung, C. S., Yang, C. Y., Hsieh, H. J., Wei, J. N., Ma, W. Y., & Li, H. Y. (2012). BMI correlates better to visceral fat and insulin sensitivity than BAI. *Obesity*, *20*(6), 1141. https://doi.org/10.1038/oby.2012.86

Hunter, G. R., Gower, B. A., & Kane, B. L. (2010). Age Related Shift in Visceral Fat. *International Journal of Body Composition Research*, *8*(3), 103–108.

Heeren, J., Scheja, L., 2021. Metabolic-associated fatty liver disease and lipoprotein metabolism. Mol. Metab. 50, 101238. https://doi.org/10.1016/j.molmet.2021.101238

., Ebner, L., Heverhagen, J.T., Christe, A., 2015. State-of-the-art imaging ver fibrosis and cirrhosis: A comprehensive review of current applications future perspectives. Eur. J. Radiol. open 2, 90–100. s://doi.org/10.1016/j.ejro.2015.05.002

Huh, Y., Cho, Y.J., Nam, G.E., 2022. Recent Epidemiology and Risk Factors of Nonalcoholic Fatty Liver Disease. J. Obes. Metab. Syndr. 31, 17–27. https://doi.org/10.7570/jomes22021

Hussain, M.M., 2014. Intestinal lipid absorption and lipoprotein formation. Curr. Opin. Lipidol. 25, 200–206. https://doi.org/10.1097/MOL.0000000000000084

Ichida, H., Imamura, H., Yoshioka, R., Mizuno, T., Mise, Y., Kuwatsuru, R., Kawasaki, S., Saiura, A., 2021. Re-evaluation of the Couinaud classification for segmental anatomy of the right liver, with particular attention to the relevance of cranio-caudal boundaries. Surgery 169, 333–340. https://doi.org/10.1016/j.surg.2020.08.029

Idalsoaga, F., Kulkarni, A. V, Mousa, O.Y., Arrese, M., Arab, J.P., 2020. Non-alcoholic Fatty Liver Disease and Alcohol-Related Liver Disease: Two Intertwined Entities. Front. Med. 7, 448. https://doi.org/10.3389/fmed.2020.00448

Ikram, H., Jaffar, S. R., Hayat, A., Khattak, M., Majeed, N., & Naeem, A. (2022). Fibroscan Compared to Aspartate Aminotransferase to Platelet Ratio Index (APRI) and Aspartate Aminotransferase to Alanine Aminotransferase Ratio (AST to ALT) in the Assessment of Liver Fibrosis in Patients with Non Alcoholic Fatty Liver Disease in a Terti. *Pakistan Armed Forces Medical Journal*, *72*(2), 776–780. https://doi.org/10.51253/pafmj.v72i2.7152

Iizuka, K., 2021. The Roles of Carbohydrate Response Element Binding Protein in the Relationship between Carbohydrate Intake and Diseases. Int. J. Mol. Sci. 22. https://doi.org/10.3390/ijms222112058

Imamura, F., Fretts, A.M., Marklund, M., Ardisson Korat, A. V, Yang, W.-S., Lankinen, M., Qureshi, W., Helmer, C., Chen, T.-A., Virtanen, J.K., Wong, K., Bassett, J.K., Murphy, R., Tintle, N., Yu, C.I., Brouwer, I.A., Chien, K.-L., Chen, Y.-Y., Wood, A.C., Del Gobbo, L.C., Djousse, L., Geleijnse, J.M., Giles, G.G., de Goede, J., Gudnason, V., Harris, W.S., Hodge, A., Hu, F., Koulman, A., Laakso, M., Lind, L., Lin, H.-J., McKnight, B., Rajaobelina, K., Riserus, U., Robinson, J.G., Samieri, C., Senn, M., Siscovick, D.S., Soedamah-Muthu, , Sotoodehnia, N., Sun, Q., Tsai, M.Y., Tuomainen, T.-P., Uusitupa, M., enknecht, L.E., Wareham, N.J., Wu, J.H.Y., Micha, R., Lemaitre, R.N., affarian, D., Forouhi, N.G., 2020. Fatty acids in the de novo lipogenesis way and incidence of type 2 diabetes: A pooled analysis of prospective

cohort studies. PLoS Med. 17, e1003102. https://doi.org/10.1371/journal.pmed.1003102

Iqbal, U., Perumpail, B.J., Akhtar, D., Kim, D., Ahmed, A., 2019. The Epidemiology, Risk Profiling and Diagnostic Challenges of Nonalcoholic Fatty Liver Disease. Medicines. https://doi.org/10.3390/medicines6010041

Jang, S., Lee, C.H., Choi, K.M., Lee, J., Choi, J.W., Kim, K.A., Park, C.M., 2011. Correlation of fatty liver and abdominal fat distribution using a simple fat computed tomography protocol. World J. Gastroenterol. 17, 3335–3341. https://doi.org/10.3748/wjg.v17.i28.3335

Jang, S., Lee, C. H., Choi, K. M., Lee, J., Choi, J. W., Kim, K. A., & Park, C. M. (2011). Correlation of fatty liver and abdominal fat distribution using a simple fat computed tomography protocol. *World Journal of Gastroenterology*, *17*(28), 3335–3341. https://doi.org/10.3748/wjg.v17.i28.3335

Ju, S. H., & Yi, H. S. (2022). Implication of Sex Differences in Visceral Fat for the Assessment of Incidence Risk of Type 2 Diabetes Mellitus. *Diabetes and Metabolism Journal*, *46*(3), 414–416. https://doi.org/10.4093/dmj.2022.0089

Jung, C. H., Rhee, E. J., Kwon, H., Chang, Y., Ryu, S., & Lee, W. Y. (2020). Visceral-to-subcutaneous abdominal fat ratio is associated with nonalcoholic fatty liver disease and liver fibrosis. *Endocrinology and Metabolism*, *35*(1), 165–176. https://doi.org/10.3803/EnM.2020.35.1.165

Jura, M., & Kozak, L. P. (2016). Obesity and related consequences to ageing. *Age (Dordrecht, Netherlands)*, *38*(1), 23. https://doi.org/10.1007/s11357-016-9884-3

Khoonsari, M., Mohammad Hosseini Azar, M., Ghavam, R., Hatami, K., Asobar, M., Gholami, A., Rajabi, A., Safarnezhad Tameshkel, F., Amirkalali, B., Sohrabi, M., 2017. Clinical Manifestations and Diagnosis of Nonalcoholic Fatty Liver Disease. Iran. J. Pathol. 12, 99–105.

Kim, T. H., Jeong, C. W., Lee, C. S., Noh, S. H., Lim, D. W., Kim, J. W., Kim, H. J., & Kim, Y. R. (2023). Association between Body Composition Contents and Hepatic Fibrosis in Sarcopenic Obesity. *Journal of Clinical Medicine*, *12*(13). s://doi.org/10.3390/jcm12134279

Cholankeril, G., Li, A.A., Kim, W., Tighe, S.P., Hameed, B., Kwo, P.Y., ison, S.A., Younossi, Z.M., Ahmed, A., 2019. Trends in hospitalizations hronic liver disease-related liver failure in the United States, 2005-2014.

Liver Int. Off. J. Int. Assoc. Study Liver 39, 1661–1671. https://doi.org/10.1111/liv.14135

Kinner, S., Reeder, S.B., Yokoo, T., 2016. Quantitative Imaging Biomarkers of NAFLD. Dig. Dis. Sci. 61, 1337–1347. https://doi.org/10.1007/s10620-016-4037-1

Lee, D.H., 2017. Imaging evaluation of non-alcoholic fatty liver disease: focused on quantification. Clin. Mol. Hepatol. 23, 290–301. https://doi.org/10.3350/cmh.2017.0042

Lee, S.S., Park, S.H., 2014. Radiologic evaluation of nonalcoholic fatty liver disease. World J. Gastroenterol. 20, 7392–7402. https://doi.org/10.3748/wjg.v20.i23.7392

Lee, Y., Doumouras, A.G., Yu, J., Brar, K., Banfield, L., Gmora, S., Anvari, M., Hong, D., 2019. Complete Resolution of Nonalcoholic Fatty Liver Disease After Bariatric Surgery: A Systematic Review and Meta-analysis. Clin. Gastroenterol. Hepatol. Off. Clin. Pract. J. Am. Gastroenterol. Assoc. 17, 1040-1060.e11. https://doi.org/10.1016/j.cgh.2018.10.017

Lent-Schochet, D., Jialal, I., 2022. Biochemistry, Lipoprotein Metabolism. Treasure Island (FL).

Laura SOLDEVILA1*. (2020). *Association between visceral abdominal fat accumulation and severity of liver fibrosis in nondiabetic individuals coinfected by HIV and HCV*.

Lee, S. P., Ahn, Y. W., Lee, O. Y., Lee, K. N., Sohn, W., Lee, H. L., Jun, D. W., Yoon, B. C., & Choi, H. S. (2014). The relationship between colonic diverticulosis and abdominal visceral and subcutaneous fat accumulation measured by abdominal CT scan. *Turkish Journal of Gastroenterology*, *25*(2), 192–197. https://doi.org/10.5152/tjg.2014.4581

Lee, Y. A., Wallace, M. C., & Friedman, S. L. (2015). Pathobiology of liver fibrosis: a translational success story. *Gut*, *64*(5), 830–841. https://doi.org/10.1136/gutjnl-2014-306842

Li, G., Tang, L. J., Zhu, P. W., Huang, O. Y., Rios, R. S., Zheng, K. I., Chen, S. D., H. L., Targher, G., Byrne, C. D., Pan, X. Y., & Zheng, M. H. (2022). LA3 rs738409 C>G Variant Influences the Association Between Visceral and Significant Fibrosis in Biopsy-proven Nonalcoholic Fatty Liver ase. *Journal of Clinical and Translational Hepatology*, *10*(3), 439–448.

https://doi.org/10.14218/JCTH.2021.00286

Liedtke, C., Nevzorova, Y. A., Luedde, T., Zimmermann, H., Kroy, D., Strnad, P., Berres, M.-L., Bernhagen, J., Tacke, F., Nattermann, J., Spengler, U., Sauerbruch, T., Wree, A., Abdullah, Z., Tolba, R. H., Trebicka, J., Lammers, T., Trautwein, C., & Weiskirchen, R. (2022). Liver Fibrosis—From Mechanisms of Injury to Modulation of Disease . In *Frontiers in Medicine* (Vol. 8). https://www.frontiersin.org/articles/10.3389/fmed.2021.814496

Liutsko, L., Leonov, S., Pashenko, A., & Polikanova, I. (2023). *Frequency of Practicing of Different Types of Physical Activity, BMI and Tobacco/Alcohol Consumption Relationship: How They Are Associated with Our Physical and*.

Lopez-Pentecost, M., Hallmark, B., Thomson, C., Chilton, F., & Garcia, D. (2022). Abstract 5956: Relationship between fatty acid intake and liver steatosis and fibrosis among overweight and obese Mexican-origin adults. *Cancer Research*, *82*(12_Supplement), 5956–5956. https://doi.org/10.1158/1538-7445.am2022-5956

Lubis, A. I., Putri, S. E., Safrida, S., Ayunda, H. M., & Iskandar, A. (2021). Relationship between Body Mass Index and Visceral Fat of Participants EXPO 2021 Universitas Teuku Umar. *Journal of Nutrition Science*, *2*(2), 48. https://doi.org/10.35308/jns.v2i2.4377

Li, J., Zou, B., Yeo, Y.H., Feng, Y., Xie, X., Lee, D.H., Fujii, H., Wu, Y., Kam, L.Y., Ji, F., Li, X., Chien, N., Wei, M., Ogawa, E., Zhao, C., Wu, X., Stave, C.D., Henry, L., Barnett, S., Takahashi, H., Furusyo, N., Eguchi, Y., Hsu, Y.-C., Lee, T.-Y., Ren, W., Qin, C., Jun, D.W., Toyoda, H., Wong, V.W.-S., Cheung, R., Zhu, Q., Nguyen, M.H., 2019. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: a systematic review and meta-analysis. lancet. Gastroenterol. Hepatol. 4, 389–398. https://doi.org/10.1016/S2468-1253(19)30039-1

Li, Q., Dhyani, M., Grajo, J.R., Sirlin, C., Samir, A.E., 2018. Current status of imaging in nonalcoholic fatty liver disease. World J. Hepatol. 10, 530–542. https://doi.org/10.4254/wjh.v10.i8.530

ɗ, P., Raman, S.S., Lassman, C., Sayre, J., Ghobrial, R.M., Busuttil, R.W., ɓ, S., Lu, D.S.K., 2004. Macrovesicular Hepatic Steatosis in Living ıted Liver Donors: Correlation between CT and Histologic Findings. iology 230, 276–280. https://doi.org/10.1148/radiol.2301021176

Lorente, S., Hautefeuille, M., Sanchez-Cedillo, A., 2020. The liver, a functionalized vascular structure. Sci. Rep. 10, 16194. https://doi.org/10.1038/s41598-020-73208-8

Lu, Y.-C., Chang, C.-C., Wang, C.-P., Hung, W.-C., Tsai, I.-T., Tang, W.-H., Wu, C.-C., Wei, C.-T., Chung, F.-M., Lee, Y.-J., Hsu, C.-C., 2020. Circulating fatty acid-binding protein 1 (FABP1) and nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus. Int. J. Med. Sci. 17, 182–190. https://doi.org/10.7150/ijms.40417

Makbul, A., Pradana,S., Soebagijo, A., Putu, M., Wismandari., Hendra,Z., Ruli,R., Olivia, C., Marina,E., 2021. Panduan Pengelolaan Dislipidemia di Indonesia. Indonesia. Tim Penyusun Buku Pedoman Pengelolaan Dislipidemia di Indonesia.

Mahaling, D.U., Basavaraj, M.M., Bika, A.J., 2013. Comparison of lipid profile in different grades of non-alcoholic fatty liver disease diagnosed on ultrasound. Asian Pac. J. Trop. Biomed. 3, 907. https://doi.org/10.1016/S2221-1691(13)60177-X

M. Maheshwari. (2015). *Review Article Relationship between Cardiovascular Parameter and General and Visceral Obesity Indices- A Review*.

Martínez-Escudé, A., Pera, G., Costa-Garrido, A., Rodríguez, L., Arteaga, I., Expósito-Martínez, C., Torán-Monserrat, P., & Caballería, L. (2021). TSH levels as an independent risk factor for NAFLD and liver fibrosis in the general population. *Journal of Clinical Medicine*, *10*(13). https://doi.org/10.3390/jcm10132907

Mateo-Gallego, R., Bea, A. M., Jarauta, E., Perez-Ruiz, M. R., & Civeira, F. (2012). Age and sex influence the relationship between waist circumference and abdominal fat distribution measured by bioelectrical impedance. *Nutrition Research (New York, N.Y.)*, *32*(6), 466–469. https://doi.org/10.1016/j.nutres.2012.05.004

Méndez-Sánchez, N., Cerda-Reyes, E., Higuera-de-la-Tijera, F., Salas-García, A. K., Cabrera-Palma, S., Cabrera-Álvarez, G., Cortez-Hernández, C., Pérez-dondo, L. A., Purón-González, E., Coronado-Alejandro, E., Panduro, A., ríguez-Hernández, H., Cruz-Ramón, V. C., Valencia-Rodríguez, A., Qi, łamdan-Pérez, N., Aguilar-Olivos, N. E., Barranco-Fragoso, B., Ramírez-ez, O., & Vera-Barajas, A. (2020). Dyslipidemia as a risk factor for liver

fibrosis progression in a multicentric population with non-alcoholic steatohepatitis. *F1000Research*, *9*. https://doi.org/10.12688/f1000research.21918.1

Mansour-Ghanaei, R., Mansour-Ghanaei, F., Naghipour, M., Joukar, F., 2019. Biochemical markers and lipid profile in nonalcoholic fatty liver disease patients in the PERSIAN Guilan cohort study (PGCS), Iran. J. Fam. Med. Prim. Care 8, 923. https://doi.org/10.4103/JFMPC.JFMPC_243_18

Mathew, R.P., Venkatesh, S.K., 2018. Liver vascular anatomy: a refresher. Abdom. Radiol. (New York) 43, 1886–1895. https://doi.org/10.1007/s00261-018-1623-z

Maurice, J., Manousou, P., 2018. Non-alcoholic fatty liver disease. Clin. Med. 18, 245–250. https://doi.org/10.7861/clinmedicine.18-3-245

Miwah,R., Ken,K., Tadashi,N., Tohru,Y., Tohru,F., Iichiro,S.2014. Clinical Significance of Visceral AdiposityAssessed by Computed Tomography: A Japanese Perspective

Murag, S., Ahmed, A., Kim, D., 2021. Recent Epidemiology of Nonalcoholic Fatty Liver Disease. Gut Liver 15, 206–216. https://doi.org/10.5009/gnl20127

Nassir, F., Rector, R.S., Hammoud, G.M., Ibdah, J.A., 2015. Pathogenesis and Prevention of Hepatic Steatosis. Gastroenterol. Hepatol. (N. Y). 11, 167–175.

Naveau, S., Dobrin, A. S., Balian, A., Njiké-Nakseu, M., Nohra, P., Asnacios, A., Prévot, S., & Perlemuter, G. (2013). Body Fat Distribution and Risk Factors for Fibrosis in Patients with Alcoholic Liver Disease. *Alcoholism: Clinical and Experimental Research*, *37*(2), 332–338. https://doi.org/10.1111/j.1530-0277.2012.01927.x

Nazare, J. A., Smith, J. D., Borel, A. L., Haffner, S. M., Balkau, B., Ross, R., Massien, C., Alméras, N., & Després, J. P. (2012). Ethnic influences on the relations between abdominal subcutaneous and visceral adiposity, liver fat, and cardiometabolic risk profile: The international study of prediction of intra-abdominal adiposity and its relationship with cardiometabolic risk/intra-abdominal adiposity. *American Journal of Clinical Nutrition*, *96*(4), 714–726. s://doi.org/10.3945/ajcn.112.035758

ao, L., Zhang, Y., Xu, J., Zhang, Y., Zhang, X., Du, Y., Sun, Z., & Wang, 2021). Correlation between the distribution of abdominal, pericardial and cutaneous fat and muscle and age and gender in a middle-aged and

elderly population. *Diabetes, Metabolic Syndrome and Obesity*, *14*, 2201–2208. https://doi.org/10.2147/DMSO.S299171

Nishizawa, A., Cuelho, A., De Farias-Itao, D. S., Campos, F. M., Leite, R. E. P., Ferretti-Rebustini, R. E. L., Grinberg, L. T., Nitrini, R., Jacob-Filho, W., Pasqualucci, C. A., & Suemoto, C. K. (2019). Direct measurements of abdominal visceral fat and cognitive impairment in late life: Findings from an autopsy study. *Frontiers in Aging Neuroscience*, *11*(MAY). https://doi.org/10.3389/fnagi.2019.00109

Natesan, V., Kim, S.-J., 2021. Lipid Metabolism, Disorders and Therapeutic Drugs - Review. Biomol. Ther. (Seoul). 29, 596–604. https://doi.org/10.4062/biomolther.2021.122

Oni, E.T., Figueredo, V., Aneni, E., Veladar, E., McEvoy, J.W., Blaha, M.J., Blumenthal, R.S., Conceicao, R.D., Carvalho, J.A.M., Santos, R.D., Nasir, K., 2020. Non-Alcoholic Fatty Liver Disease Modifies Serum Gamma-Glutamyl Transferase in Cigarette Smokers. J. Clin. Med. Res. 12, 472–482. https://doi.org/10.14740/jocmr3932

Paige, J.S., Bernstein, G.S., Heba, E., Costa, E.A.C., Fereirra, M., Wolfson, T., Gamst, A.C., Valasek, M.A., Lin, G.Y., Han, A., Erdman, J.W.J., O'Brien, W.D.J., Andre, M.P., Loomba, R., Sirlin, C.B., 2017. A Pilot Comparative Study of Quantitative Ultrasound, Conventional Ultrasound, and MRI for Predicting Histology-Determined Steatosis Grade in Adult Nonalcoholic Fatty Liver Disease. AJR. Am. J. Roentgenol. 208, W168–W177. https://doi.org/10.2214/AJR.16.16726

Pei, K., Gui, T., Kan, D., Feng, H., Jin, Y., Yang, Y., Zhang, Q., Du, Z., Gai, Z., Wu, J., Li, Y., 2020. An Overview of Lipid Metabolism and Nonalcoholic Fatty Liver Disease. Biomed Res. Int. 2020, 4020249. https://doi.org/10.1155/2020/4020249

Pérez-Montes de Oca, A., Julián, M. T., Pera, G., Caballería, L., Morillas, R., Torán, P., Expósito, C., Franch-Nadal, J., Mauricio, D., & Alonso, N. (2022). Dysglycemia in young women attenuates the protective effect against fatty disease. *Frontiers in Endocrinology*, *13*. s://doi.org/10.3389/fendo.2022.971864

G., 2022. Role of Ultrasound Methods for the Assessment of NAFLD. J. Med. 11. https://doi.org/10.3390/jcm11154581

Polyzos, S.A., Kountouras, J., Mantzoros, C.S., 2019. Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics. Metabolism. 92, 82–97. https://doi.org/10.1016/j.metabol.2018.11.014

Ponziani, F.R., Pecere, S., Gasbarrini, A., Ojetti, V., 2015. Physiology and pathophysiology of liver lipid metabolism. Expert Rev. Gastroenterol. Hepatol. 9, 1055–1067. https://doi.org/10.1586/17474124.2015.1056156

Pouwels, S., Sakran, N., Graham, Y., Leal, A., Pintar, T., Yang, W., Kassir, R., Singhal, R., Mahawar, K., Ramnarain, D., 2022. Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss. BMC Endocr. Disord. 22, 63. https://doi.org/10.1186/s12902-022-00980-1

Rhee, E.-J., Kim, H.C., Kim, J.H., Lee, E.Y., Kim, B.J., Kim, E.M., Song, Y., Lim, J.H., Kim, H.J., Choi, S., Moon, M.K., Na, J.O., Park, K.-Y., Oh, M.S., Han, S.Y., Noh, J., Yi, K.H., Lee, S.-H., Hong, S.-C., Jeong, I.-K., 2019. 2018 Guidelines for the management of dyslipidemia. Korean J. Intern. Med. 34, 723–771. https://doi.org/10.3904/kjim.2019.188

Ramírez-Manent, J. I., Martínez-Almoyna, E., López, C., Busquets-Cortés, C., González San Miguel, H., & López-González, Á. A. (2022). Relationship between Insulin Resistance Risk Scales and Non-Alcoholic Fatty Liver Disease and Liver Fibrosis Scales in 219,477 Spanish Workers. *Metabolites*, *12*(11). https://doi.org/10.3390/metabo12111093

Samovski, D., Abumrad, N.A., 2019. Regulation of lipophagy in NAFLD by cellular metabolism and CD36. J. Lipid Res. 60, 755–757. https://doi.org/10.1194/jlr.C093674

Sanders, F.W.B., Griffin, J.L., 2016. De novo lipogenesis in the liver in health and disease: more than just a shunting yard for glucose. Biol. Rev. Camb. Philos. Soc. 91, 452–468. https://doi.org/10.1111/brv.12178

Sanyal, D., Mukherjee, P., Raychaudhuri, M., Ghosh, S., Mukherjee, S., Chowdhury, S., 2015. Profile of liver enzymes in non-alcoholic fatty liver disease in patients with impaired glucose tolerance and newly detected eated type 2 diabetes. Indian J. Endocrinol. Metab. 19, 597–601. s://doi.org/10.4103/2230-8210.163172

R., Pierce, N., Koppe, S., 2018. Obesity and nonalcoholic fatty liver ase: current perspectives. Diabetes. Metab. Syndr. Obes. 11, 533–542.

https://doi.org/10.2147/DMSO.S146339

Seonah,J., Chang,L., Kyung,M., Jongmee,L., Jae,W.,Kyeong,A., Cheol,M. 2011. Correlation of Fatty Liver and Abdominal Fat Distribution Using A Simple Fat Computed Tomography Protocol

Silveira, L. S., Monteiro, P. A., Antunes, B. de M. M., Seraphim, P. M., Fernandes, R. A., Christofaro, D. G. D., & Júnior, I. F. F. (2013). Intra-abdominal fat is related to metabolic syndrome and non-alcoholic fat liver disease in obese youth. *BMC Pediatrics*, *13*(1). https://doi.org/10.1186/1471-2431-13-115

STAELS, B., RATZIU, V., SANYAL, A. J., FRANCQUE, S., HARRISON, S. A., ROUDOT, A., BROZEK, J., HAJJI, Y., MEGNIEN, S., HUM, D. W., BIRMAN, P., HANF, R., & CARIOU, B. (2019). 278-LB: Type 2 Diabetes (T2D) as a Risk Factor for NASH and Significant Liver Fibrosis (F>2) in an International Cohort of 2,363 Patients with Metabolic Steatosis. *Diabetes*, *68*(Supplement_1). https://doi.org/10.2337/db19-278-lb

Sharma, P., Arora, A., 2020. Clinical presentation of alcoholic liver disease and non-alcoholic fatty liver disease: spectrum and diagnosis. Transl. Gastroenterol. Hepatol. 5, 19. https://doi.org/10.21037/tgh.2019.10.02

Sherwood, L., 2016. Human Physiology : from cells to system, Ninth Edition 9th ed. Cengage Learning, Belmont, CA.

Sibulesky, L., 2013. Normal liver anatomy. Clin. liver Dis. 2, S1–S3. https://doi.org/10.1002/cld.124

Smith, G.I., Shankaran, M., Yoshino, M., Schweitzer, G.G., Chondronikola, M., Beals, J.W., Okunade, A.L., Patterson, B.W., Nyangau, E., Field, T., Sirlin, C.B., Talukdar, S., Hellerstein, M.K., Klein, S., 2020. Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease. J. Clin. Invest. 130, 1453–1460. https://doi.org/10.1172/JCI134165

Song, Z., Xiaoli, A.M., Yang, F., 2018. Regulation and Metabolic Significance of De Novo Lipogenesis in Adipose Tissues. Nutrients. https://doi.org/10.3390/nu10101383

Tajiri, K., Shimizu, Y., 2013. Liver physiology and liver diseases in the elderly. ld J. Gastroenterol. https://doi.org/10.3748/wjg.v19.i46.8459

r, J.A., Kurtz, D.M., Schoenleber, S.J., West, C.P., Montori, V.M., 2007. igure is presented}Ultrasound-Based Transient Elastography for the ection of Hepatic Fibrosis: Systematic Review and Meta-analysis. Clin.

Gastroenterol. Hepatol. 5, 1214–1220. https://doi.org/10.1016/j.cgh.2007.07.020

Tominaga, K., Kurata, J. H., Chen, Y. K., Fujimoto, E., Miyagawa, S., Abe, I., & Kusano, Y. (1995). Prevalence of fatty liver in Japanese children and relationship to obesity. *Digestive Diseases and Sciences*, *40*(9), 2002–2009. https://doi.org/10.1007/bf02208670

Turck, D., Bresson, J., Burlingame, B., Dean, T., Fairweather-Tait, S., Heinonen, M., Hirsch-Ernst, K. I., Mangelsdorf, I., McArdle, H. J., Naska, A., Neuhäuser-Berthold, M., Nowicka, G., Pentieva, K., Sanz, Y., Sjödin, A., Stern, M., Tomé, D., Van Loveren, H., Vinceti, M., … Siani, A. (2017). Stablor® and reduction of visceral fat while maintaining lean mass: evaluation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006. *EFSA Journal*, *15*(2). https://doi.org/10.2903/j.efsa.2017.4723

Unger, L. W., Forstner, B., Schneglberger, S., Muckenhuber, M., Eigenbauer, E., Scheiner, B., Mandorfer, M., Trauner, M., & Reiberger, T. (2019). Patterns and prevalence of dyslipidemia in patients with different etiologies of chronic liver disease. *Wiener Klinische Wochenschrift*, *131*(17–18), 395–403. https://doi.org/10.1007/s00508-019-01544-5

Urata, N., Kawanaka, M., Nishino, K., Ishii, K., Tanikawa, T., Suehiro, M., Sasai, T., Haruma, K., Kawamoto, H., Nakamura, J., Manabe, N., & Kamada, T. (2020). Fatty liver, and not visceral fat, is more associated with liver fibrosis and diabetes in non-obese japanese individuals: A cross-sectional study. *Life*, *10*(9), 1–11. https://doi.org/10.3390/life10090175

Villa, G., Owusu, D., Smith, C., Azumah, M., Abdullahi, A., Phillips, S., Sayeed, L., Austin, H., Chadwick, D., Phillips, R. O., & Geretti, A. M. (2022). Liver steatosis and fibrosis in people with human immunodeficiency virus in West Africa and the relationship with hepatitis B virus coinfection. *Hepatology Communications*, *6*(11), 3036–3051. https://doi.org/10.1002/hep4.2000

Wang, M.-D., Wang, N.-Y., Zhang, H.-L., Sun, L.-Y., Xu, Q.-R., Liang, L., Li, C., Huang, D.-S., Zhu, H., Yang, T., 2021. Fatty acid transport protein-5 (FATP5) ciency enhances hepatocellular carcinoma progression and metastasis by ogramming cellular energy metabolism and regulating the AMPK-mTOR aling pathway. Oncogenesis 10, 74. https://doi.org/10.1038/s41389-021-64-5

Xu, F., Earp, J. E., Adami, A., Lofgren, I. E., Delmonico, M. J., Greene, G. W., & Riebe, D. (2022). The Sex and Race/Ethnicity-Specific Relationships of Abdominal Fat Distribution and Anthropometric Indices in US Adults. *International Journal of Environmental Research and Public Health*, *19*(23). https://doi.org/10.3390/ijerph192315521

Zarini, G., Sales Martinez, S., Campa, A., Sherman, K., Tamargo, J., Hernandez Boyer, J., Teeman, C., Johnson, A., Degarege, A., Greer, P., Liu, Q., Huang, Y., Mandler, R., Choi, D., & Baum, M. K. (2020). Sex Differences, Cocaine Use, and Liver Fibrosis among African Americans in the Miami Adult Studies on HIV Cohort. *Journal of Women's Health*, *29*(9), 1176–1183. https://doi.org/10.1089/jwh.2019.7954

Zhang, X., He, Z., Si, Q., Hu, X., Yang, L., Gu, X., Du, L., Wang, L., Pan, L., Li, Y., Li, J., Yang, B., & Gu, X. (2022). The Association of Sarcopenia and Visceral Obesity with Lean Nonalcoholic Fatty Liver Disease in Chinese Patients with Type 2 Diabetes Mellitus. *Journal of Diabetes Research*, *2022*. https://doi.org/10.1155/2022/2229139

Zhu, C., Huang, D., Ma, H., Qian, C., You, H., Bu, L., & Qu, S. (2022). High-Sensitive CRP Correlates With the Severity of Liver Steatosis and Fibrosis in Obese Patients With Metabolic Dysfunction Associated Fatty Liver Disease. *Frontiers in Endocrinology*, *13*. https://doi.org/10.3389/fendo.2022.848937

Zhang, J.-Z., Cai, J.-J., Yu, Y., She, Z.-G., Li, H., 2019. Nonalcoholic Fatty Liver Disease: An Update on the Diagnosis. Gene Expr. 19, 187–198. https://doi.org/10.3727/105221619X15553433838609

Zhang, Y.N., Fowler, K.J., Hamilton, G., Cui, J.Y., Sy, E.Z., Balanay, M., Hooker, J.C., Szeverenyi, N., Sirlin, C.B., 2018. Liver fat imaging-a clinical overview of ultrasound, CT, and MR imaging. Br. J. Radiol. 91, 20170959. https://doi.org/10.1259/bjr.20170959

Zhao, L., Li, Yuqi, Ding, Q., Li, Yanping, Chen, Y., Ruan, X.Z., 2021. CD36 Senses Dietary Lipids and Regulates Lipids Homeostasis in the Intestine. Front. Physiol. 12, 669279. https://doi.org/10.3389/fphys.2021.669279

LAMPIRAN 1 REKOMENDASI PERSETUJUAN ETIK

KEMENTERIAN PENDIDIKAN, KEBUDAYAAN, RISET DAN TEKNOLOGI
UNIVERSITAS HASANUDDIN FAKULTAS KEDOKTERAN
KOMITE ETIK PENELITIAN UNIVERSITAS HASANUDDIN
RSPTN UNIVERSITAS HASANUDDIN
RSUP Dr. WAHIDIN SUDIROHUSODO MAKASSAR
Sekretariat : Lantai 2 Gedung Laboratorium Terpadu
JL.PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KM.10 MAKASSAR 90245.
Contact Person: dr. Agussalim Bukhari.,M.Med.PhD, SpGK TELP. 081241850858, 0411 5780103, Fax : 0411-581431

REKOMENDASI PERSETUJUAN ETIK

Nomor : 604/UN4.6.4.5.31/ PP36/ 2023

Tanggal: 30 Agustus 2023

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

No Protokol	UH23080600	No Sponsor	
Peneliti Utama	**dr. Dina Wati Amaliah Rahman, S.Ked**	Sponsor	
Judul Peneliti	KORELASI FATTY LIVER DENGAN DISTRIBUSI LEMAK VISCERAL ABDOMEN PADA CT SCAN ABDOMEN BERDASARKAN IMT, PROFIL LIPID DARAH DAN FIBROSCAN		
No Versi Protokol	**1**	Tanggal Versi	**16 Agustus 2023**
No Versi PSP	**1**	Tanggal Versi	**16 Agustus 2023**
Tempat Penelitian	RSUP Dr. Wahidin Sudirohusodo Makassar		
Jenis Review	☐ Exempted ☒ Expedited ☐ Fullboard Tanggal	Masa Berlaku **30 Agustus 2023** sampai **30 Agustus 2024**	Frekuensi review lanjutan
Ketua KEP Universitas Hasanuddin	Nama **Prof.Dr.dr. Suryani As'ad, M.Sc.,Sp.GK (K)**	Tanda tangan	
Sekretaris KEP Universitas Hasanuddin	Nama **dr. Agussalim Bukhari, M.Med.,Ph.D.,Sp.GK (K)**	Tanda tangan	

Kewajiban Peneliti Utama:

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 Jam dan dilengkapi dalam 7 hari dan Lapor SUSAR dalam 72 Jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari prokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan

LAMPIRAN 2 DATA SAMPEL PENELITIAN

Jenis Kelamin

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Laki-laki	22	34.9	34.9	34.9
	Perempuan	41	65.1	65.1	100.0
	Total	63	100.0	100.0	

Usia

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	<=45	29	46.0	46.0	46.0
	>45	34	54.0	54.0	100.0
	Total	63	100.0	100.0	

IMT

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Obesitas	18	28.6	28.6	28.6
	Non Obesitas	45	71.4	71.4	100.0
	Total	63	100.0	100.0	

Fatty Liver

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Ringan	52	82.5	82.5	82.5
	Sedang	5	7.9	7.9	90.5
	Parah	6	9.5	9.5	100.0
	Total	63	100.0	100.0	

Profil Lipid

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Non Dyslipidemia	3	4.8	4.8	4.8
	Dyslipidemia	60	95.2	95.2	100.0
	Total	63	100.0	100.0	

Lemak Visceral

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Ya	50	79.4	79.4	79.4
	Tidak	13	20.6	20.6	100.0
	Total	63	100.0	100.0	

Fibroscan

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Non Fibroscan	36	57.1	57.1	57.1
	Fibroscan	27	42.9	42.9	100.0
	Total	63	100.0	100.0	

Crosstab

			Lemak Visceral		
			Ya	Tidak	Total
Jenis Kelamin	Laki-laki	Count	19	3	22
		% within Jenis Kelamin	86.4%	13.6%	100.0%
	Perempuan	Count	31	10	41
		% within Jenis Kelamin	75.6%	24.4%	100.0%
		Count	50	13	63
		% within Jenis Kelamin	79.4%	20.6%	100.0%

Chi-Square Tests

	Value	df	Asymp. Sig. (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	1.011[a]	1	.315		
Continuity Correction[b]	.461	1	.497		
Likelihood Ratio	1.064	1	.302		
Fisher's Exact Test				.515	.253
Linear-by-Linear Association	.995	1	.319		
N of Valid Cases	63				

a. 1 cells (25.0%) have expected count less than 5. The minimum expected count is 4.54.

b. Computed only for a 2x2 table

rosstab

			Fibroscan		
			Non Fibroscan	Fibroscan	Total
Jenis Kelamin	Laki-laki	Count	13	9	22
		% within Jenis Kelamin	59.1%	40.9%	100.0%
	Perempuan	Count	23	18	41
		% within Jenis Kelamin	56.1%	43.9%	100.0%
Total		Count	36	27	63
		% within Jenis Kelamin	57.1%	42.9%	100.0%

Chi-Square Tests

	Value	df	Asymp. Sig. (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	.052[a]	1	.819		
Continuity Correction[b]	.000	1	1.000		
Likelihood Ratio	.052	1	.819		
Fisher's Exact Test				1.000	.517
Linear-by-Linear n	.052	1	.820		
Cases	63				

0.0%) have expected count less than 5. The minimum expected count is 9.43.

ed only for a 2x2 table

Crosstab

			Lemak Visceral		
			Ya	Tidak	Total
IMT	Obesitas	Count	16	2	18
		% within IMT	88.9%	11.1%	100.0%
	Non Obesitas	Count	34	11	45
		% within IMT	75.6%	24.4%	100.0%
Total		Count	50	13	63
		% within IMT	79.4%	20.6%	100.0%

Chi-Square Tests

	Value	df	Asymp. Sig. (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	1.396[a]	1	.237		
Continuity Correction[b]	.700	1	.403		
Likelihood Ratio	1.533	1	.216		
Fisher's Exact Test				.316	.205
Linear-by-Linear Association	1.374	1	.241		
N of Valid Cases	63				

a. 1 cells (25.0%) have expected count less than 5. The minimum expected count is 3.71.

b. Computed only for a 2x2 table

Crosstab

			Fibroscan		
			Non Fibroscan	Fibroscan	Total
IMT	Obesitas	Count	12	6	18
		% within IMT	66.7%	33.3%	100.0%
	Non Obesitas	Count	24	21	45
		% within IMT	53.3%	46.7%	100.0%
		Count	36	27	63
		% within IMT	57.1%	42.9%	100.0%

Chi-Square Tests

	Value	df	Asymp. Sig. (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	.933[a]	1	.334		
Continuity Correction[b]	.468	1	.494		
Likelihood Ratio	.949	1	.330		
Fisher's Exact Test				.405	.248
Linear-by-Linear Association	.919	1	.338		
N of Valid Cases	63				

a. 0 cells (0.0%) have expected count less than 5. The minimum expected count is 7.71.

b. Computed only for a 2x2 table

Crosstab

			Lemak Visceral		Total
			Ya	Tidak	
Usia	<=45	Count	22	7	29
		% within Usia	75.9%	24.1%	100.0%
	>45	Count	28	6	34
		% within Usia	82.4%	17.6%	100.0%
Total		Count	50	13	63
		% within Usia	79.4%	20.6%	100.0%

Chi-Square Tests

	Value	df	Asymp. Sig. (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	.403[a]	1	.526		
Continuity Correction[b]	.104	1	.747		
Likelihood Ratio	.401	1	.526		
Fisher's Exact Test				.550	.372
Linear-by-Linear n	.396	1	.529		
Cases	63				

0.0%) have expected count less than 5. The minimum expected count is 5.98.

ed only for a 2x2 table

Crosstab

			Fibroscan		
			Non Fibroscan	Fibroscan	Total
Usia	<=45	Count	19	10	29
		% within Usia	65.5%	34.5%	100.0%
	>45	Count	17	17	34
		% within Usia	50.0%	50.0%	100.0%
Total		Count	36	27	63
		% within Usia	57.1%	42.9%	100.0%

Chi-Square Tests

	Value	df	Asymp. Sig. (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	1.539[a]	1	.215		
Continuity Correction[b]	.970	1	.325		
Likelihood Ratio	1.550	1	.213		
Fisher's Exact Test				.307	.162
Linear-by-Linear Association	1.514	1	.218		
N of Valid Cases	63				

a. 0 cells (0.0%) have expected count less than 5. The minimum expected count is 12.43.

b. Computed only for a 2x2 table

Crosstab

			Lemak Visceral		
			Ya	Tidak	Total
Profil Lipid	Non Dyslipidemia	Count	3	0	3
		% within Profil Lipid	100.0%	0.0%	100.0%
	Dyslipidemia	Count	47	13	60
		% within Profil Lipid	78.3%	21.7%	100.0%
		Count	50	13	63
		% within Profil Lipid	79.4%	20.6%	100.0%

Chi-Square Tests

	Value	df	Asymp. Sig. (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	.819[a]	1	.365		
Continuity Correction[b]	.030	1	.862		
Likelihood Ratio	1.425	1	.233		
Fisher's Exact Test				1.000	.494
Linear-by-Linear Association	.806	1	.369		
N of Valid Cases	63				

a. 2 cells (50.0%) have expected count less than 5. The minimum expected count is .62.

b. Computed only for a 2x2 table

Crosstab

			Fibroscan		
			Non Fibroscan	Fibroscan	Total
Profil Lipid	Non Dyslipidemia	Count	1	2	3
		% within Profil Lipid	33.3%	66.7%	100.0%
	Dyslipidemia	Count	35	25	60
		% within Profil Lipid	58.3%	41.7%	100.0%
Total		Count	36	27	63
		% within Profil Lipid	57.1%	42.9%	100.0%

Chi-Square Tests

	Value	df	Asymp. Sig. (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	.729[a]	1	.393		
Continuity Correction[b]	.066	1	.798		
Likelihood Ratio	.724	1	.395		
Fisher's Exact Test				.572	.392
Linear-by-Linear n	.718	1	.397		
Cases	63				

50.0%) have expected count less than 5. The minimum expected count is 1.29.

ed only for a 2x2 table

Crosstab

			Lemak Visceral		
			Ya	Tidak	Total
Fatty Liver	Ringan	Count	42	10	52
		% within Fatty Liver	80.8%	19.2%	100.0%
	Sedang	Count	4	1	5
		% within Fatty Liver	80.0%	20.0%	100.0%
	Parah	Count	4	2	6
		% within Fatty Liver	66.7%	33.3%	100.0%
Total		Count	50	13	63
		% within Fatty Liver	79.4%	20.6%	100.0%

Chi-Square Tests

	Value	df	Asymp. Sig. (2-sided)
Pearson Chi-Square	.655[a]	2	.721
Likelihood Ratio	.588	2	.745
Linear-by-Linear Association	.548	1	.459
N of Valid Cases	63		

a. 4 cells (66.7%) have expected count less than 5. The minimum expected count is 1.03.

rosstab

			Fibroscan		
			Non Fibroscan	Fibroscan	Total
Fatty Liver	Ringan	Count	30	22	52
		% within Fatty Liver	57.7%	42.3%	100.0%
	Sedang	Count	4	1	5
		% within Fatty Liver	80.0%	20.0%	100.0%
	Parah	Count	2	4	6
		% within Fatty Liver	33.3%	66.7%	100.0%
		Count	36	27	63
		% within Fatty Liver	57.1%	42.9%	100.0%

Chi-Square Tests

	Value	df	Asymp. Sig. (2-sided)
Pearson Chi-Square	2.462[a]	2	.292
Likelihood Ratio	2.553	2	.279
Linear-by-Linear Association	.484	1	.487
N of Valid Cases	63		

a. 4 cells (66.7%) have expected count less than 5. The minimum expected count is 2.14.

Descriptives

	Jenis Kelamin			Statistic	Std. Error
HU	Laki-laki	Mean		-14.725	2.4164
		95% Confidence Interval for Mean	Lower Bound	-19.751	
			Upper Bound	-9.700	
		5% Trimmed Mean		-13.716	
		Median		-12.165	
		Variance		128.453	
		Std. Deviation		11.3337	
		Minimum		-44.6	
		Maximum		-3.0	
		Range		41.6	
		Interquartile Range		10.5	
		Skewness		-1.751	.491
		Kurtosis		2.681	.953
	Perempuan	Mean		-19.812	2.8756
		95% Confidence Interval for Mean	Lower Bound	-25.624	
			Upper Bound	-14.000	
		5% Trimmed Mean		-17.150	
		Median		-14.300	
		Variance		339.038	
		Std. Deviation		18.4130	
		Minimum		-111.5	
		Maximum		-3.0	
		Range		108.5	

		Interquartile Range		12.3	
		Skewness		-3.458	.369
		Kurtosis		15.333	.724
Visceral	Laki-laki	Mean		.9032	.09472
		95% Confidence Interval for Mean	Lower Bound	.7062	
			Upper Bound	1.1002	
		5% Trimmed Mean		.8877	
		Median		.8400	
		Variance		.197	
		Std. Deviation		.44428	
		Minimum		.24	
		Maximum		1.84	
		Range		1.60	
		Interquartile Range		.55	
		Skewness		.651	.491
		Kurtosis		-.136	.953
	Perempuan	Mean		.6663	.09637
		95% Confidence Interval for Mean	Lower Bound	.4716	
			Upper Bound	.8611	
		5% Trimmed Mean		.5814	
		Median		.5400	
		Variance		.381	
		Std. Deviation		.61705	
		Minimum		.20	
		Maximum		4.27	
		Range		4.07	
		Interquartile Range		.35	
		Skewness		5.196	.369
		Kurtosis		30.605	.724

Descriptives

	Usia			Statistic	Std. Error
HU	<=45	Mean		-17.622	2.3653
		95% Confidence Interval for Mean	Lower Bound	-22.467	
			Upper Bound	-12.777	
		5% Trimmed Mean		-16.317	
		Median		-12.000	
		Variance		162.249	
		Std. Deviation		12.7377	
		Minimum		-57.6	
		Maximum		-4.8	
		Range		52.8	
		Interquartile Range		10.6	
		Skewness		-1.751	.434
		Kurtosis		2.667	.845
	>45	Mean		-18.389	3.2809
		95% Confidence Interval for Mean	Lower Bound	-25.064	
			Upper Bound	-11.714	
		5% Trimmed Mean		-15.631	
		Median		-14.550	
		Variance		365.979	
		Std. Deviation		19.1306	
		Minimum		-111.5	
		Maximum		-3.0	
		Range		108.5	
		Interquartile Range		13.8	
		Skewness		-3.741	.403
		Kurtosis		17.371	.788
Visceral	<=45	Mean		.5945	.03946
		95% Confidence Interval for Mean	Lower Bound	.5136	
			Upper Bound	.6753	
		5% Trimmed Mean		.5934	
		Median		.6000	
		Variance		.045	

		Std. Deviation		.21251	
		Minimum		.20	
		Maximum		1.03	
		Range		.83	
		Interquartile Range		.36	
		Skewness		.017	.434
		Kurtosis		-.655	.845
	>45	Mean		.8809	.12535
		95% Confidence Interval for Mean	Lower Bound	.6259	
			Upper Bound	1.1359	
		5% Trimmed Mean		.7825	
		Median		.6650	
		Variance		.534	
		Std. Deviation		.73092	
		Minimum		.25	
		Maximum		4.27	
		Range		4.02	
		Interquartile Range		.62	
		Skewness		3.246	.403
		Kurtosis		13.845	.788

Descriptives

	IMT			Statistic	Std. Error
HU	Obesitas	Mean		-18.927	5.8413
		95% Confidence Interval for Mean	Lower Bound	-31.251	
			Upper Bound	-6.603	
		5% Trimmed Mean		-14.669	
		Median		-11.765	
		Variance		614.175	
		Std. Deviation		24.7826	
		Minimum		-111.5	
		Maximum		-3.0	
		Range		108.5	
		Interquartile Range		9.9	
		Skewness		-3.445	.536

		Kurtosis		12.831	1.038
	Non Obesitas	Mean		-17.679	1.7650
		95% Confidence Interval for Mean	Lower Bound	-21.236	
			Upper Bound	-14.122	
		5% Trimmed Mean		-16.605	
		Median		-13.800	
		Variance		140.193	
		Std. Deviation		11.8403	
		Minimum		-57.6	
		Maximum		-4.6	
		Range		53.0	
		Interquartile Range		12.9	
		Skewness		-1.454	.354
		Kurtosis		2.074	.695
Visceral	Obesitas	Mean		.9539	.21443
		95% Confidence Interval for Mean	Lower Bound	.5015	
			Upper Bound	1.4063	
		5% Trimmed Mean		.8115	
		Median		.7000	
		Variance		.828	
		Std. Deviation		.90976	
		Minimum		.20	
		Maximum		4.27	
		Range		4.07	
		Interquartile Range		.55	
		Skewness		3.162	.536
		Kurtosis		11.348	1.038
	Non Obesitas	Mean		.6671	.05050
		95% Confidence Interval for Mean	Lower Bound	.5653	
			Upper Bound	.7689	
		5% Trimmed Mean		.6377	
		Median		.5700	
		Variance		.115	
		Std. Deviation		.33879	
		Minimum		.24	

Maximum	1.80	
Range	1.56	
Interquartile Range	.42	
Skewness	1.356	.354
Kurtosis	2.115	.695

Descriptives

	Fatty Liver			Statistic	Std. Error
HU	Ringan	Mean		-12.419	.7567
		95% Confidence Interval for Mean	Lower Bound	-13.938	
			Upper Bound	-10.900	
		5% Trimmed Mean		-12.313	
		Median		-11.550	
		Variance		29.771	
		Std. Deviation		5.4563	
		Minimum		-25.0	
		Maximum		-3.0	
		Range		22.0	
		Interquartile Range		8.0	
		Skewness		-.330	.330
		Kurtosis		-.605	.650
	Sedang	Mean		-30.394	1.2634
		95% Confidence Interval for Mean	Lower Bound	-33.902	
			Upper Bound	-26.886	
		5% Trimmed Mean		-30.451	
		Median		-31.100	
		Variance		7.981	
		Std. Deviation		2.8250	
		Minimum		-33.7	
		Maximum		-26.1	
		Range		7.6	
		Interquartile Range		4.8	
		Skewness		.788	.913
		Kurtosis		.992	2.000
	Parah	Mean		-56.412	11.3124

		95% Confidence Interval for Mean	Lower Bound	-85.491	
			Upper Bound	-27.332	
		5% Trimmed Mean		-54.226	
		Median		-43.950	
		Variance		767.818	
		Std. Deviation		27.7095	
		Minimum		-111.5	
		Maximum		-40.7	
		Range		70.8	
		Interquartile Range		30.3	
		Skewness		-2.194	.845
		Kurtosis		4.887	1.741
Visceral	Ringan	Mean		.7396	.08268
		95% Confidence Interval for Mean	Lower Bound	.5736	
			Upper Bound	.9056	
		5% Trimmed Mean		.6605	
		Median		.6100	
		Variance		.355	
		Std. Deviation		.59618	
		Minimum		.20	
		Maximum		4.27	
		Range		4.07	
		Interquartile Range		.40	
		Skewness		4.342	.330
		Kurtosis		24.338	.650
	Sedang	Mean		.7480	.13230
		95% Confidence Interval for Mean	Lower Bound	.3807	
			Upper Bound	1.1153	
		5% Trimmed Mean		.7539	
		Median		.8100	
		Variance		.088	
		Std. Deviation		.29584	
		Minimum		.36	
		Maximum		1.03	
		Range		.67	

		Interquartile Range		.58	
		Skewness		-.453	.913
		Kurtosis		-2.130	2.000
	Parah	Mean		.8317	.23490
		95% Confidence Interval for Mean	Lower Bound	.2278	
			Upper Bound	1.4355	
		5% Trimmed Mean		.8063	
		Median		.7300	
		Variance		.331	
		Std. Deviation		.57538	
		Minimum		.28	
		Maximum		1.84	
		Range		1.56	
		Interquartile Range		.95	
		Skewness		1.172	.845
		Kurtosis		1.374	1.741

Descriptives

	Profil Lipid			Statistic	Std. Error
HU	Non Dyslipidemia	Mean		-8.810	1.8435
		95% Confidence Interval for Mean	Lower Bound	-16.742	
			Upper Bound	-.878	
		5% Trimmed Mean		.	
		Median		-8.000	
		Variance		10.195	
		Std. Deviation		3.1930	
		Minimum		-12.3	
		Maximum		-6.1	
		Range		6.2	
		Interquartile Range		.	
		Skewness		-1.068	1.225
		Kurtosis		.	.
	Dyslipidemia	Mean		-18.497	2.1485
		95% Confidence Interval for Mean	Lower Bound	-22.796	
			Upper Bound	-14.198	

		5% Trimmed Mean		-16.399	
		Median		-13.950	
		Variance		276.966	
		Std. Deviation		16.6423	
		Minimum		-111.5	
		Maximum		-3.0	
		Range		108.5	
		Interquartile Range		11.7	
		Skewness		-3.406	.309
		Kurtosis		16.170	.608
Visceral	Non Dyslipidemia	Mean		.8867	.18774
		95% Confidence Interval for Mean	Lower Bound	.0789	
			Upper Bound	1.6944	
		5% Trimmed Mean		.	
		Median		1.0000	
		Variance		.106	
		Std. Deviation		.32517	
		Minimum		.52	
		Maximum		1.14	
		Range		.62	
		Interquartile Range		.	
		Skewness		-1.378	1.225
		Kurtosis		.	.
	Dyslipidemia	Mean		.7422	.07499
		95% Confidence Interval for Mean	Lower Bound	.5921	
			Upper Bound	.8922	
		5% Trimmed Mean		.6654	
		Median		.6150	
		Variance		.337	
		Std. Deviation		.58087	
		Minimum		.20	
		Maximum		4.27	
		Range		4.07	
		Interquartile Range		.41	
		Skewness		4.122	.309

		Kurtosis		23.003	.608

Descriptives

	Lemak Visceral			Statistic	Std. Error
HU	Ya	Mean		-17.954	2.4544
		95% Confidence Interval for Mean	Lower Bound	-22.887	
			Upper Bound	-13.022	
		5% Trimmed Mean		-15.474	
		Median		-12.835	
		Variance		301.196	
		Std. Deviation		17.3550	
		Minimum		-111.5	
		Maximum		-3.0	
		Range		108.5	
		Interquartile Range		10.7	
		Skewness		-3.662	.337
		Kurtosis		17.241	.662
	Tidak	Mean		-18.348	3.4616
		95% Confidence Interval for Mean	Lower Bound	-25.891	
			Upper Bound	-10.806	
		5% Trimmed Mean		-17.954	
		Median		-15.800	
		Variance		155.774	
		Std. Deviation		12.4809	
		Minimum		-40.8	
		Maximum		-3.0	
		Range		37.8	
		Interquartile Range		18.1	
		Skewness		-.829	.616
		Kurtosis		-.326	1.191
Visceral	Ya	Mean		.8620	.08341
		95% Confidence Interval for Mean	Lower Bound	.6944	
			Upper Bound	1.0296	
		5% Trimmed Mean		.7779	
		Median		.7150	

		Variance		.348	
		Std. Deviation		.58982	
		Minimum		.42	
		Maximum		4.27	
		Range		3.85	
		Interquartile Range		.44	
		Skewness		4.248	.337
		Kurtosis		22.947	.662
	Tidak	Mean		.3146	.01608
		95% Confidence Interval for Mean	Lower Bound	.2796	
			Upper Bound	.3496	
		5% Trimmed Mean		.3168	
		Median		.3300	
		Variance		.003	
		Std. Deviation		.05797	
		Minimum		.20	
		Maximum		.39	
		Range		.19	
		Interquartile Range		.09	
		Skewness		-.674	.616
		Kurtosis		-.493	1.191

Descriptives

	Fibroscan			Statistic	Std. Error
HU	Non Fibroscan	Mean		-16.183	1.9021
		95% Confidence Interval for Mean	Lower Bound	-20.045	
			Upper Bound	-12.322	
		5% Trimmed Mean		-14.919	
		Median		-11.800	
		Variance		130.244	
		Std. Deviation		11.4124	
		Minimum		-57.6	
		Maximum		-3.0	
		Range		54.6	
		Interquartile Range		9.8	

		Skewness		-1.956	.393
		Kurtosis		4.342	.768
	Fibroscan	Mean		-20.506	4.0969
		95% Confidence Interval for Mean	Lower Bound	-28.927	
			Upper Bound	-12.084	
		5% Trimmed Mean		-17.363	
		Median		-14.300	
		Variance		453.182	
		Std. Deviation		21.2881	
		Minimum		-111.5	
		Maximum		-3.0	
		Range		108.5	
		Interquartile Range		13.3	
		Skewness		-3.259	.448
		Kurtosis		13.049	.872
Visceral	Non Fibroscan	Mean		.8189	.11613
		95% Confidence Interval for Mean	Lower Bound	.5831	
			Upper Bound	1.0546	
		5% Trimmed Mean		.7178	
		Median		.6200	
		Variance		.485	
		Std. Deviation		.69677	
		Minimum		.20	
		Maximum		4.27	
		Range		4.07	
		Interquartile Range		.43	
		Skewness		3.789	.393
		Kurtosis		17.512	.768
	Fibroscan	Mean		.6559	.06289
		95% Confidence Interval for Mean	Lower Bound	.5267	
			Upper Bound	.7852	
		5% Trimmed Mean		.6374	
		Median		.5600	
		Variance		.107	
		Std. Deviation		.32677	

	Minimum	.24	
	Maximum	1.48	
	Range	1.24	
	Interquartile Range	.52	
	Skewness	.700	.448
	Kurtosis	-.066	.872

			Jenis Kelamin	Usia	IMT	Profil Lipid	Fibroscan
Spearman's rho	Jenis Kelamin	Correlation Coefficient	1.000	.125	-.021	.149	.029
		Sig. (2-tailed)	.	.329	.870	.244	.822
		N	63	63	63	63	63
	Usia	Correlation Coefficient	.125	1.000	.050	-.207	.156
		Sig. (2-tailed)	.329	.	.695	.104	.221
		N	63	63	63	63	63
	IMT	Correlation Coefficient	-.021	.050	1.000	.024	.122
		Sig. (2-tailed)	.870	.695	.	.855	.342
		N	63	63	63	63	63
	Profil Lipid	Correlation Coefficient	.149	-.207	.024	1.000	-.108
		Sig. (2-tailed)	.244	.104	.855	.	.401
		N	63	63	63	63	63
	Fibroscan	Correlation Coefficient	.029	.156	.122	-.108	1.000
		Sig. (2-tailed)	.822	.221	.342	.401	.
		N	63	63	63	63	63
	HU	Correlation Coefficient	-.179	-.001	-.117	-.189	-.089
		Sig. (2-tailed)	.627	.678	.769	.483	.487
		N	63	63	63	63	63

	Visceral	Correlation Coefficient	-.364**	.186	-.167	-.137	-.107
		Sig. (2-tailed)	.072	.078	.097	.401	.405
		N	63	63	63	63	63

LAMPIRAN 3 CURRICULUM VITAE

CURRICULUM VITAE

A. Data Pribadi

- Nama : dr. Dina Wati Amaliah Rahman
- Agama : Islam
- Tempat/Tgl Lahir : Makassar/ 19 September 1991
- Alamat : Jl. Tamangapa Raya 3, Perum. Taman Makassar Indah A2/2, Bangkala, Manggala, Kota Makassar
- Nama Ayah/Ibu : dr.Abd.Rahman Rahim/ DR.Mujizatullah, M.p.d.i
- Suami : dr. Arif Sumanto S. Dai
- Anak : Assyifa Rahmania Arif Dai

B. Riwayat Pendidikan

- SD : SDN Labuang Baji II
- SMP : SMPN 16 Bekasi
- SMA : SMAN 02 Makassar
- Perguruan Tinggi : Fakultas Kedokteran Universitas Muhammadiyah Makassar
- Profesi Dokter : Fakultas Kedokteran Universitas Muhammadiyah Makassar
- PPDS : Departemen Radiologi Fakultas Kedokteran Universitas Hasanuddin Periode Januari 2020

C. Riwayat Pekerjaan

- Dokter Umum di Klinik Melviana, Bekasi 2017-2018
- Dokter Umum di Puskesmas Bongomeme, Desa Dulamayo, Kec. Bongomeme, Kab Gorontalo 2018-2019

D. Makalah pada Seminar/ Konferens Ilmiah Nasional:

"Traumatic Diaphragmatic Hernia in a 15-Years Old Adolescent" pada ertemuan Ilmiah Tahunan – Perhimpunan Dokter Spesialis Radiologi linik Indonesia ke-16 "Role of Radiology in Emergency Setting : Current nd Future Challenges" Manado, 11-12 Maret 202